VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2012

Jun 1, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2012-05-30

Reporting Person: BOGER JOSHUA S (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-05-30	Common Stock	M	4000	$15.60	Acquired	636895	Direct
2012-05-30	Common Stock	S	1700	$57.92	Disposed	635195	Direct
2012-05-30	Common Stock	S	800	$58.75	Disposed	634395	Direct
2012-05-30	Common Stock	S	900	$59.98	Disposed	633495	Direct
2012-05-30	Common Stock	S	600	$60.43	Disposed	632895	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-05-30	Stock Option	$15.60	M	4000	Disposed	2013-01-17	Common Stock (4000)	Direct
2012-06-01	Stock Option	$59.55	A	20000	Acquired	2022-05-31	Common Stock (20000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	13286	Indirect
Common Stock	300000	Indirect

Footnotes

F1: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $57.92 (range $57.28 to $58.12).

F3: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4: Open market sales reported on this line occurred at a weighted average price of $58.75 (range $58.31 to $59.30).

F5: Open market sales reported on this line occurred at a weighted average price of $59.98 (range $59.32 to $60.25).

F6: Open market sales reported on this line occurred at a weighted average price of $60.43 (range $60.32 to $60.59).

F7: Common stock held in grantor retained annuity trusts.

F8: Fully vested.